🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Cancer Chemotherapy Cancer Cell

1/4 Article of the month: First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase 1 dose exploration. Hans Prenen tinyurl.com/23btbhxd

#GI25 NET a rapidly evolving field. Starter-NET terminated early due to efficacy! Although major question of the control arm? Lanreotide + Everolimus more than doubled PFS for first line NET compared to everolimus alone. Given comparison to everolimus and not SSA based therapy

Important alert: 🚨 The COMPETE study has met its primary endpoint! ITM-11, a targeted radiopharmaceutical therapy, demonstrated a clinically relevant and statistically significant improvement in PFS compared to everolimus in patients with G1-G2 GEP-NETs itm-radiopharma.com/news/press-rel…

Functional imaging in NECs and much more... Check out this excellent paper. Lots of goodies in here such as >90% of NECs and G3 NETs FDG PET pos. Also, 66% of NECs pos on SSTR PET. What does that mean? The SSTR is not (yet) a good NEC target. Willem Lybaert erc.bioscientifica.com/view/journals/…

Today is a good day! Our new paper on a Belgian cohort of 283 high grade neuroendocrine neoplasms receives Thor Halfdanarson's stamp of approval. More on NET G3 vs NEC, functional imaging,... through erc.bioscientifica.com/view/journals/… NETwerk Willem Lybaert

⌛️Stay tuned for the 2025 INCA/ENETS Symposium during the 22nd Annual ENETS Conference in Krakow, Poland, on March 6th, from 16:15 - 17:45 CET. 👉We will focus on ways to improve NEN research globally. ✅Read the agenda: incalliance.org/annual-inca-en… Follow us for news!

NET Cancer Day ENETS On the way to Krakau for a very beautiful program#do not miss the research talk of Laura Mariën from Belgium on Liquid Biopsies in NET🥰

🔥Nivolumab and Ipilimuma approved by EMA for advanced hepatocellular carcinoma 🔥 👇ec.europa.eu/health/documen… 👉great news for our patients > more options in 1st line 😅amazing: approval in 🇪🇺by EMA before 🇺🇸by FDA ESMO - Eur. Oncology EASL Education ILCA #livertwitter

#enets2025 ENETS-INCA joint session Thor Halfdanarson on Meaningful involvement of pts in NEN research Meredith Cummins NeuroEndocrine Cancer Australia on pts partnering 🌎 Timon Vandamme on aligning researcher & pt priorities Simron Singh on improving global research 🔑Essential to partner w advocates

📌INCA/ENETS Symposium 2025 on March 6th: A consensus on how collaboration between NET researchers and patient advocates can facilitate a patient-centered healthcare for NETs. 👉Get a snapshot of the insights from NET researchers and NET patient advocates:

🚀 #ENETS2025 Highlights! Prof Dr Timon Vandamme explores two game-changing trials in NET treatment: 🔹 COMPETE: PRRT (177Lu-edotreotide) becomes a new standard of care. 🔹 OCLURANDOM: Unprecedented 63% response rate in pancreatic NETs. 🌟 Liquid biopsy innovation wins poster award!

📺 #ENETS 2025 – In Depth! Prof Dr Timon Vandamme reviews the CABINET trial results, recently published in NEJM: 🔹 Cabozantinib significantly improves PFS in pancreatic & extra-pancreatic NETs 🔹 18% ORR in pancreatic NETs 🔹 Manageable side effects 🔹 OS not significant due to

We zijn nog bezig met het verslag van ons bezoek aan ENETS, maar we hebben onder andere het onderzoek van de Belgische Laura Mariën mogen aanhoren. Laura's onderzoek heet NET-IMPRESS en ze hoopt moleculaire veranderingen in het bloed op te sporen,

zodat de ziekte sneller gevonden kan worden. blog.uantwerpen.be/fbd/neuro-endo…

🚀 #ENETS2025 Highlights! Prof Dr Timon Vandamme presents KINETICS: a large real-world study on lanreotide monotherapy in GEP-NETs with Ki-67 >10%.: 🔹 Data from 7 centres (2015–2022) 🔹 Ki-67 >10% vs. ≤10% 🔹 GI vs. pancreatic primary 🔹 Results due end 2025

PRRT vs Everolimus for 🫁 carcinoids. The ongoing phase III GETNE-LEVEL study. Bringing new hopes for patients with #neuroendocrinecancer Grupo GETNE NET- ESPAÑA NET Cancer Day CarcinoidCancer CCF ENETS NANETS Vall d’Hebron Institute of Oncology (VHIO) @https://link.springer.com/10.1186/s12885-025-13941-3

Interested in precision medicine and #BTC #cholangiocarcinoma? Read our paper ESMO Open! authors.elsevier.com/sd/article/S20…

We’re hiring! Join our lab to work on cutting-edge TCR-based therapies in neuroendocrine tumors (NETs). Passionate about immunotherapy and translational cancer research? Apply by April 17, 2025! #Postdoc #Immunotherapy #CancerResearch #TCR #NETs #Hiring reclutamento.ict.uniba.it/contratti-di-r…

Lot to unpack from the excellent NORDIC NEC2. - ORR: 31% for NEC (mostly plat/eto) - this is NOT SCLC - ORR: 27% for G3 NETs (mostly TMZ-based) - Immediate progression: 41% of NECs, 21% G3 NETs - PFS: 3.4 m NEC; 7.4 G3 NET NECs are really bad cancers! nature.com/articles/s4141…